HOUSTON, Aug. 10, 2006 (PRIMEZONE) -- Encysive Pharmaceuticals (NASDAQ:ENCY - News) was notified today that the European Commission has adopted the decision granting marketing authorization for THELIN(r)(1) (sitaxentan sodium(2)) in the European Union.
The Company is awaiting the formal decision letter from the European Commission. Following receipt, which is expected soon, the Company will provide further information.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com.
The Encysive Pharmaceuticals Inc. company logo can be found at http://media.primezone.com/prs/single/?pkgid=843
(1) THELIN is an E.U. registered trademark of Encysive Pharmaceuticals Inc.
(2) ``Sitaxentan’’ sodium is the spelling recognized by the World Health Organization for Encysive Pharmaceuticals’ sitaxsentan sodium.
This press release contains ``forward-looking statements’’ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these statements by the fact that they use words such as ``will,’' ``anticipate,’' ``estimate,’' ``expect,’' ``project,’' ``intend,’' ``plan,’' ``believe,’' ``target,’' ``forecast,’' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business prospects. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are decisions by regulatory authorities regarding whether and when to approve our drug applications for THELIN(tm) (sitaxsentan sodium), and their decisions regarding labeling and other matters that could affect the availability and commercial potential of THELIN; the speed with which regulatory authorizations, pricing approvals, and product launches for THELIN may be achieved in the European Union; competitive product developments that may affect THELIN; the ability to successfully market THELIN; difficulties or delays in manufacturing, packaging or distributing THELIN; the impact of existing and future regulatory provisions on product exclusivity, including orphan drug exclusivity; legislation or regulations in countries within the European Union affecting THELIN’s pricing, reimbursement or access; Encysive’s ability to protect its patents and other intellectual property for THELIN; foreign currency exchange rate fluctuations; governmental laws and regulations affecting Encysive’s domestic and international operations, including tax obligations, as well as other risks, trends and uncertainties facing Encysive such as those set forth in its reports on Forms 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks, trends and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore you should not rely on any such forward-looking statements. Furthermore, Encysive undertakes no duty to update or revise these forward-looking statements. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Contact: Encysive Pharmaceuticals Investors: Ann Tanabe, VP, Investor Relations and Corporate Communications (713) 796-8822 The Trout Group Marcy Strickler (212) 477-9007 ext. 27 Media: BMC Communications Dan Budwick (212) 477-9007 ext. 14
Source: Encysive Pharmaceuticals Inc.
